Neuroscience Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      +30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4

       

      CHRONIC MIGRAINE

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

      UK-BCM-240035. DOP: April 2024.

      carousel1

      UNDERSTANDING
      CHRONIC MIGRAINE

      How is chronic migraine defined and what are the key symptoms?

      Read more
      carousel3

      QUALITY OF LIFE

      What is the burden of chronic migraine and how does it affect a patient’s quality of life?

      Read more
      carousel2

      DIAGNOSIS

      How can you accurately recognise and diagnose chronic migraine?

      Read more
      carousel4

      PATIENT PERSPECTIVE

      Listen to a patient’s experience of chronic migraine and review self-care strategies

      Read more

      BOTOX® is a treatment option for the prophylaxis of headaches in adults with chronic migraine, with proven efficacy and a safety and tolerability profile from over 30 years of global experience across multiple indications.1-5

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5

      How likely are you to prescribe BOTOX® for chronic migraine?

      Chronic migraine can be an incapacitating and isolating disease.6,7 Listen to Kayte, a patient with chronic migraine who describes her own experience.

      CM: chronic migraine. 

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/859/smpc.  Accessed March 2024
      6. Weatherall M W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 2015;6(3):115-123
      7. Buse D C, Manack A et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432

       

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
      5. BOTOX® Summary of Product Characteristics. Available at: https://www.medicines.org.uk /emc/product/859/smpc.  Accessed March 2024
      6. Weatherall M W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 2015;6(3):115-123
      7. Buse D C, Manack A et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432

       

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on [email protected] 

       

      Date of preparation: March 2024. UK-BCM-240033.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.